Skip to content

Investor Relations / Publications / Publications Search

Publications Search

Pisaniello AD, Nicholls SJ, Ballantyne CM, Bhatt DL, Wong ND. Eicosapentaenoic acid: atheroprotective properties and the reduction of atherosclerotic cardiovascular disease events. EMJ. 2020;5:29-36.

https://www.emjreviews.com/cardiology/symposium/eicosapentaenoic-acid-atheroprotective-properties-and-the-reduction-of-atherosclerotic-cardiovascular-disease-events/

Mason RP, Sherratt SCR. Eicosapentaenoic acid inhibits oxidation of very large density lipoproteins (VLDL) in a dose-dependent manner over time as compared to docosahexaenoic acid in vitro [abstract]. J Am Coll Cardiol. 2020;75(11 suppl 1):2238.

http://www.onlinejacc.org/content/75/11_Supplement_1/2238

Sherratt SCR, Juliano RA, Mason RP. Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. Biochimica Biophysica Acta Biomembrane. 2020; epub ahead of print.

https://www.sciencedirect.com/science/article/pii/S0005273620300791

S.C.R. Sherratt, R.A. Juliano and R.P. Mason, Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro, BBA - Biomembranes(2020)

https://doi.org/10.1016/j.bbamem.2020.183254

Boden WE, Bhatt DL, Toth PP, et al. Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics. Eur Heart J. 2020;41(24):2304–2312.

https://doi.org/10.1093/eurheartj/ehz778

Bhatt DL, Miller M, Brinton EA, Jacobson TA, Steg G, Ketchum SB, Doyle RT Jr., Juliano RA, Jiao L, Granowitz C, Tardif J-C, Olshansky B, Chung MK, Gibson CM, Giugliano RP, Budoff MJ, Ballantyne CM, on behalf of the REDUCE-IT Investigators. REDUCE-IT USA: results from the 3,146 patients randomized in the United States. Circulation. 2019; epub ahead of print.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.119.044440

Budoff MJ, Bhatt DL, Kinninger A, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020; epub ahead of print.

https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaa652/5898836

Toth PP, Philip S, Hull M, Granowitz C. Elevated triglycerides (≥150 mg/dL) and high triglycerides (200–499 mg/dL) are significant predictors of hospitalization for new-onset kidney disease: a real-world analysis of high-risk statin-treated patientsCardiorenal Med. 2019.

https://www.ncbi.nlm.nih.gov/pubmed/31450229

Mason RP, Dawoud H, Jacob RF, Sherratt SCR, Malinski T. Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statinBiomed Pharmacother. 2018;103:1231-7.
Free:

https://www.sciencedirect.com/science/article/pii/S0753332218309909

Amarin Corporation